AxSpA Literature Highlights – February 2023
Bimekizumab, Secukinumab, TNF Inhibitor, bDMARD, Achilles Enthesitis
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Bimekizumab, Secukinumab, TNF Inhibitor, bDMARD, Achilles Enthesitis
Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595
Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.
Trials. 2023 doi: 10.1186/s13063-022-06945-y
Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.
Lancet. 2023 doi: 10.1016/S0140-6736(22)02303-0
This study showed rapid and clinically meaningful improvements with bimekizumab treatment in patients experiencing active PsA and showing an inadequate response or intolerance to TNFα inhibitors. Its chief aim was to evaluate the efficacy and safety of bimekizumab in patients with an inadequate response or intolerance to TNFα inhibitors.
Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9
This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.
Rheumatol Ther. 2022 Oct 15:1–18 doi: 10.1007/s40744-022-00499-w
Results from the long-term extension of SELECT-PsA 1 show efficacy responses similar or greater with upadacitinib, 15 or 30mg, versus adalimumab through 104 weeks.
Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0
In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.
Ann Rheum Dis. 2022 2022 2022-222849
In the latest study by Brunner, et al. secukinumab demonstrated efficacy and safety in the JIA categories of ERA and JPsA. This phase 3 study aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA.
N Engl J Med. 2022;387(8):715–726. doi: 10.1056/NEJMoa2201302
Phase 3 trial of olokizumab, a direct inhibitor of the IL-6 ligand, demonstrates superiority to placebo with respect to an ACR20 response at week 12 and noninferiority to adalimumab (all combined with methotrexate), in patients with RA.
Lancet 2022 doi: 10.1016/S0140-6736(22)01212-0
Upadacitinib significantly improved the signs and symptoms of nr-axSpA compared with placebo at Week 14 in this investigation. Prior to this, upadacitinib had been shown to be effective in patients with AS. This study aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab784
Secukinumab improves the burden of heel enthesitis as assessed by patient and physician reported outcomes in patients with active SpA refractory to standard treatment. In coming to this conclusion, the ACHILLES trial aimed to demonstrate the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients.